SEC Form 4 · accession 0000899243-16-010831
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Renzi
Officer — President & CEO · Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.33 | Jan 4, 2016 | A | 283,000 | A | — | Jan 4, 2026 | Common Stock | 283,000 | 283,000 | D |
Explanation of responses
- F1The option shall vest with respect to 1/48 of the underlying shares upon each monthly anniversary of the vesting commencement date of January 1, 2016.